Hemostats Market Innovation in Flowable and Gel-Based Solutions 2032
- sachi toshniwal
- 4 hours ago
- 4 min read
The hemostats market focuses on medical products used to control bleeding during surgeries or after injuries. These products help promote clotting and are essential in various procedures, including cardiac, orthopedic, and general surgeries. Hemostats come in different forms, such as sponges, powders, gels, and patches, and are widely used in hospitals and surgical centers. The market is growing due to the increasing number of surgeries, rising trauma cases, and advancements in hemostatic technologies. North America currently leads the market, while Asia-Pacific is experiencing rapid growth due to expanding healthcare infrastructure and rising surgical needs.
According to Fortune Business Insights, the global hemostats market was valued at USD 4.75 billion in 2023 and is projected to grow from USD 5.09 billion in 2024 to USD 9.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% during the forecast period (2024–2032). In 2023, North America dominated the market with a 35.16% share.
Top Companies in the Market
Baxter (U.S.)
Integra LifeSciences (U.S.)
Stryker (U.S.)
Artivion, Inc. (U.S.)
Biom'up (U.S.)
BD (Becton, Dickinson and Company) (U.S.)
Medtronic (Ireland)
Johnson & Johnson Services, Inc. (U.S.)
Pfizer Inc. (U.S.)
Key Industry Development
In November 2023, Ethicon (a subsidiary of Johnson & Johnson Medical Devices Companies) secured CE Mark approval for its ETHIZIA Hemostatic Sealing Patch. The product is slated for launch in the EMEA region in Q1 2024.
Market Drivers & Restraints
Drivers
Rising prevalence of chronic diseases (cardiovascular disease, cancer, trauma) is increasing demand for surgical interventions and bleeding control products.
The surge in surgical procedures globally has heightened the need for effective hemostasis during operations.
Technological innovations and regulatory approvals for novel hemostats are boosting market expansion.
North America leads the global market (35.16% share in 2023) due to surgical volume and strong uptake of advanced products.
Restraints
High cost of hemostatic products and rising healthcare expenses limit wider adoption.
Clinical constraints and potential bleeding complications also hinder some applications.
Need for skilled healthcare professionals in surgical settings can act as a barrier in emerging markets.
Market Coverage & Competitive Landscape
The Fortune Business Insights report offers a comprehensive outlook through 2032, segmented by:
Product types: active, passive, combination, others
Applications: trauma, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery & others
End‑user: hospitals & ambulatory surgical centers, tactical combat casualty care centers, others
Regional segmentation: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Market Segments
The report classifies the hemostats industry into the following key categories:
By Product Type: active hemostats (e.g. thrombin‑based), passive hemostats, combination hemostats, others.
By Application: trauma, cardiovascular surgery, general surgery, plastic, orthopaedic, neurosurgery, other specialties.
By End‑User: hospitals & ASCs, tactical combat casualty care centers, others.
Market Regional Insights
North America: Dominant in 2023 with 35.16 % share (~USD 1.67 billion), powered by high surgical volume and mature healthcare systems.
Europe: Slower growth compared to Asia Pacific due to smaller patient population; moderate CAGR anticipated.
Middle East & Africa: Gradual opportunity expansion tied to improving healthcare infrastructure.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/hemostats-market-100084
Future Market Scope
Looking ahead to 2032, the hemostats market appears poised for further acceleration. From a base of USD 5.09 billion in 2024, the industry is set to nearly double by 2032 to USD 9.33 billion, at a projected CAGR of 7.9% .Growth drivers include increasing incidence of chronic diseases and trauma, ongoing innovation in formulations (e.g. thrombin-based, biodegradable matrix), and growing surgical demand especially in emerging markets .Technological advancements—such as robot‑assisted surgeries and next‑generation hemostatic agents—are expected to further fuel adoption and effectiveness. Moreover, increasing regulatory approvals and product launches (e.g. ETHIZIA patch by Ethicon in EMEA early‑2024) suggest continued momentum and product pipeline strength.
Summary
The global Hemostats Market is on an expansion trajectory from USD 4.75 billion in 2023 toward USD 9.33 billion by 2032. Major players such as Baxter, Johnson & Johnson, Medtronic, Stryker, and others dominate with strong R&D, distribution, and product diversification. Drivers include rising surgical volumes, chronic disease prevalence, and product innovations, whereas high costs and clinical constraints may temper growth. Regionally, while North America remains the largest, Asia Pacific is the fastest‑growing. Regulatory milestones like the ETHIZIA CE approval emphasise robust future momentum. Stakeholders should remain attentive to emerging markets and evolving surgical technologies as the landscape unfolds.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Comentários